Fortress Biotech, Inc. (FBIO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net revenue | 16,413 | - | 14,629 | 14,896 |
| Asset impairment charges | - | - | - | 2,649 |
| Selling, general and administrative | 38,757 | - | 21,993 | 20,823 |
| Research and development | 8,126 | - | 9,446 | 12,671 |
| Cost of goods - (excluding amortization of acquired intangible assets) | 4,939 | - | 5,285 | 6,541 |
| Amortization of acquired intangible assets | 1,064 | - | - | - |
| Total operating expenses | 52,886 | - | 36,724 | 42,684 |
| Loss from operations | -36,473 | - | -22,095 | -27,788 |
| Other income (expense) | -62 | - | 1,071 | 282 |
| Interest income | 622 | - | 589 | 734 |
| Gain from deconsolidation of subsidiary | 27,127 | - | - | - |
| Interest expense and financing fee | 2,518 | - | 6,209 | 2,122 |
| Gain (loss) on common stock warrant liabilities | -350 | - | 19 | 70 |
| Total other income (expense) | 24,819 | - | -4,530 | -1,036 |
| Income (loss) from continuing operations before income taxes, noncontrolling interest | - | - | -26,625 | - |
| Income tax expense (refund) | - | - | 69 | - |
| Net loss | -11,654 | -24,691 | -26,694 | -28,824 |
| Attributable to non-controlling interests | -27,140 | -14,107 | -13,827 | -17,876 |
| Net income (loss) attributable to fortress | 15,486 | -12,715 | -15,040 | -10,948 |
| Preferred a dividends declared and paid and/or cumulated, and fortress' share of subsidiary deemed dividends | - | 2,131 | 2,173 | - |
| Net loss attributable to common stockholders | - | -12,715 | -15,040 | - |
| Earnings per share, basic | 0.5 | -0.48 | -0.76 | -0.73 |
| Earnings per share, diluted | 0.45 | -0.48 | -0.76 | -0.73 |
| Weighted average number of shares outstanding, basic | 26,879,380 | 26,450,218 | 19,697,290 | 18,316,874 |
| Weighted average number of shares outstanding, diluted | 29,824,182 | 26,450,218 | 19,697,290 | 18,316,874 |